These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24862579)

  • 1. Combatting infectious diseases; nanotechnology as a platform for rational vaccine design.
    van Riet E; Ainai A; Suzuki T; Kersten G; Hasegawa H
    Adv Drug Deliv Rev; 2014 Jul; 74():28-34. PubMed ID: 24862579
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Designer adjuvants for enhancing the efficacy of infectious disease and cancer vaccines based on suppression of regulatory T cell induction.
    Mills KH
    Immunol Lett; 2009 Feb; 122(2):108-11. PubMed ID: 19100777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle vaccines.
    Zhao L; Seth A; Wibowo N; Zhao CX; Mitter N; Yu C; Middelberg AP
    Vaccine; 2014 Jan; 32(3):327-37. PubMed ID: 24295808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanoparticle Vaccines Against Infectious Diseases.
    Pati R; Shevtsov M; Sonawane A
    Front Immunol; 2018; 9():2224. PubMed ID: 30337923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Plant-made oral vaccines against human infectious diseases-Are we there yet?
    Chan HT; Daniell H
    Plant Biotechnol J; 2015 Oct; 13(8):1056-70. PubMed ID: 26387509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune responses to vaccines involving a combined antigen-nanoparticle mixture and nanoparticle-encapsulated antigen formulation.
    Zhang W; Wang L; Liu Y; Chen X; Liu Q; Jia J; Yang T; Qiu S; Ma G
    Biomaterials; 2014 Jul; 35(23):6086-97. PubMed ID: 24780166
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoparticles for nasal vaccination.
    Csaba N; Garcia-Fuentes M; Alonso MJ
    Adv Drug Deliv Rev; 2009 Feb; 61(2):140-57. PubMed ID: 19121350
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticles and microparticles as vaccine-delivery systems.
    Singh M; Chakrapani A; O'Hagan D
    Expert Rev Vaccines; 2007 Oct; 6(5):797-808. PubMed ID: 17931159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From plasmids to protection: a review of DNA vaccines against infectious diseases.
    Laddy DJ; Weiner DB
    Int Rev Immunol; 2006; 25(3-4):99-123. PubMed ID: 16818367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overview of recent DNA vaccine development for fish.
    Kurath G
    Dev Biol (Basel); 2005; 121():201-13. PubMed ID: 15962483
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bacteriophage T4 nanoparticles for vaccine delivery against infectious diseases.
    Tao P; Zhu J; Mahalingam M; Batra H; Rao VB
    Adv Drug Deliv Rev; 2019 May; 145():57-72. PubMed ID: 29981801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A small jab - a big effect: nonspecific immunomodulation by vaccines.
    Benn CS; Netea MG; Selin LK; Aaby P
    Trends Immunol; 2013 Sep; 34(9):431-9. PubMed ID: 23680130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccine adjuvant systems: enhancing the efficacy of sub-unit protein antigens.
    Perrie Y; Mohammed AR; Kirby DJ; McNeil SE; Bramwell VW
    Int J Pharm; 2008 Dec; 364(2):272-80. PubMed ID: 18555624
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Micro/nanoparticle adjuvants for antileishmanial vaccines: present and future trends.
    Badiee A; Heravi Shargh V; Khamesipour A; Jaafari MR
    Vaccine; 2013 Jan; 31(5):735-49. PubMed ID: 23219436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Freeze-drying of ovalbumin loaded mesoporous silica nanoparticle vaccine formulation increases antigen stability under ambient conditions.
    Mody KT; Mahony D; Cavallaro AS; Stahr F; Qiao SZ; Mahony TJ; Mitter N
    Int J Pharm; 2014 Apr; 465(1-2):325-32. PubMed ID: 24583208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New adjuvants for human vaccines.
    Mbow ML; De Gregorio E; Valiante NM; Rappuoli R
    Curr Opin Immunol; 2010 Jun; 22(3):411-6. PubMed ID: 20466528
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: Nanoparticle Vaccines Against Infectious Diseases.
    Reljic R; González-Fernández Á
    Front Immunol; 2019; 10():2615. PubMed ID: 31787982
    [No Abstract]   [Full Text] [Related]  

  • 18. Nanotechnology solutions for mucosal immunization.
    Chadwick S; Kriegel C; Amiji M
    Adv Drug Deliv Rev; 2010 Mar; 62(4-5):394-407. PubMed ID: 19931581
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complex correlates of protection after vaccination.
    Plotkin SA
    Clin Infect Dis; 2013 May; 56(10):1458-65. PubMed ID: 23386629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
    Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
    Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.